Ad
VYGR Quote Trading Chart Voyager Therapeutics Inc.
home / stock / vygr / vygr quote
Quote | Voyager Therapeutics Inc. (NASDAQ:VYGR)
| Last: | $6.37 |
|---|---|
| Change Percent: | 0.16% |
| Open: | $6.44 |
| Close: | $6.37 |
| High: | $6.69 |
| Low: | $6.36 |
| Volume: | 314,016 |
| Last Trade Date Time: | 12/09/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
VYGR Last Twenty Trading Days
| Last | Open | Close | High | Low | Volume | Date |
|---|---|---|---|---|---|---|
| $6.37 | $6.44 | $6.37 | $6.69 | $6.36 | 314,016 | 12-09-2024 |
| $6.45 | $6.28 | $6.45 | $6.58 | $6.26 | 364,602 | 12-06-2024 |
| $6.24 | $6.26 | $6.24 | $6.33 | $6.1339 | 366,566 | 12-05-2024 |
| $6.29 | $6.53 | $6.29 | $6.53 | $6.24 | 515,143 | 12-04-2024 |
| $6.57 | $6.93 | $6.57 | $7.05 | $6.47 | 821,921 | 12-03-2024 |
| $6.93 | $7.11 | $6.93 | $7.4436 | $6.85 | 1,142,648 | 12-02-2024 |
| $6.86 | $6.27 | $6.86 | $7.03 | $6.266 | 1,190,212 | 11-29-2024 |
| $5.78 | $5.7 | $5.78 | $5.85 | $5.675 | 169,398 | 11-28-2024 |
| $5.78 | $5.7 | $5.78 | $5.85 | $5.675 | 169,398 | 11-27-2024 |
| $5.67 | $5.77 | $5.67 | $5.8 | $5.54 | 271,041 | 11-26-2024 |
| $5.75 | $5.69 | $5.75 | $5.92 | $5.69 | 343,308 | 11-25-2024 |
| $5.655 | $5.49 | $5.655 | $5.72 | $5.41 | 359,892 | 11-22-2024 |
| $5.43 | $5.35 | $5.43 | $5.49 | $5.19 | 483,366 | 11-21-2024 |
| $5.36 | $5.41 | $5.36 | $5.59 | $5.28 | 464,365 | 11-20-2024 |
| $5.27 | $5.37 | $5.27 | $5.375 | $5.1931 | 703,896 | 11-19-2024 |
| $5.385 | $5.65 | $5.385 | $5.65 | $5.38 | 573,354 | 11-18-2024 |
| $5.64 | $6.11 | $5.64 | $6.1499 | $5.5901 | 795,871 | 11-15-2024 |
| $6.22 | $6.73 | $6.22 | $6.775 | $6.18 | 710,785 | 11-14-2024 |
| $6.69 | $7.02 | $6.69 | $7.38 | $6.6544 | 698,275 | 11-13-2024 |
| $6.83 | $7.04 | $6.83 | $7.0507 | $6.7401 | 556,963 | 11-12-2024 |
News, Short Squeeze, Breakout and More Instantly...
Voyager Therapeutics Inc. Company Name:
VYGR Stock Symbol:
NASDAQ Market:
Voyager Therapeutics Inc. Website:
Ad
-
- Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in 2026 - - VY1706 is the fifth neuro gene therapy development candidate nominated leveraging Voyager’s IV-delivered, CNS-penetrant TRACER capsids - LE...
-
- Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s; on track to generate top-line data H1 2025 - - Recent third-party clinical data establish that an antibody can inhibit tau accumulation in the human brain; provide ...
-
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report third quarter 2024 financial and operating results after market close on Tuesday, November...